Radnostix Inc. manufactures a wide range of radioisotope focused products. The company manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. It also manufactures Cobalt-60 sealed source products. Radnostix Inc., formerly known as International Isotopes Inc., is based in IDAHO FALLS, Idaho.
| Revenue (Most Recent Fiscal Year) | $13.90M |
| Net Income (Most Recent Fiscal Year) | $0.01M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.63 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.03 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 89.41 |
| Pre-Tax Margin (Trailing 12 Months) | -1.65% |
| Net Margin (Trailing 12 Months) | -1.65% |
| Return on Equity (Trailing 12 Months) | -5.44% |
| Return on Assets (Trailing 12 Months) | -1.32% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.35 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.44 |
| Inventory Turnover (Trailing 12 Months) | 6.91 |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.01 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $0.00 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Common Shares Outstanding | 528.21M |
| Free Float | 431.55M |
| Market Capitalization | $36.97M |
| Average Volume (Last 20 Days) | 0.04M |
| Beta (Past 60 Months) | 0.94 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 18.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |